skip to Main Content

Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring

GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading. GW Pharmaceuticals GWPH, +10.22%  reported second-quarter sales of $68.4 million for Epidiolex, which uses…

Read More

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress

PRESS RELEASE Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S.  - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH,…

Read More
Back To Top
×Close search